Drug intelligence / Profile preview

Polyvaccinum mite

Development stage: Unknown
Lead developer: IBSS Biomed
Modality: Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

Polyvaccinum mite is a non-specific bacterial vaccine developed by IBSS Biomed S.A. (formerly Biomed-Lublin) for the prevention of recurrent upper respiratory tract infections. Formulated as intranasal drops, it contains a suspension of heat-killed bacteria commonly associated with respiratory infections. The vaccine acts as an immunostimulant, triggering both non-specific immune responses and specific immunity against the included bacterial antigens. It is typically administered in twice-yearly courses to children, adolescents, and adults to reduce the frequency and severity of respiratory infections.

Brand names: Polyvaccinum mite
Other names: Polyvaccinum mite-Biomed-Lublin-vaccine

Beyond the preview

Go deeper on Polyvaccinum mite.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polyvaccinum mite.

Explore the full profile